Thoracic lymphangitis as an immune-related adverse event: a case report.
BMC Pulm Med
; 24(1): 299, 2024 Jun 25.
Article
en En
| MEDLINE
| ID: mdl-38918749
ABSTRACT
The efficacy of immune checkpoint inhibitors (ICIs) has been widely recognized in several cancers and is now being used in the perioperative setting for lung cancer.We recently encountered an immune-related adverse event that has not been previously reported thoracic lymphangitis, which occurred after postoperative ICI treatment for lung cancer. The patient complained of breathlessness and her condition rapidly progressed to hypoxia grade 3. Chest computed tomography revealed significant lymphostasis. With high-dose steroid treatment, the patient showed improvement.Therefore, as the frequency of neoadjuvant, adjuvant, and perioperative ICI use is expected to increase, it is crucial to understand and monitor this adverse event.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Tomografía Computarizada por Rayos X
/
Inhibidores de Puntos de Control Inmunológico
/
Neoplasias Pulmonares
/
Linfangitis
Límite:
Aged
/
Female
/
Humans
Idioma:
En
Revista:
BMC Pulm Med
Año:
2024
Tipo del documento:
Article
País de afiliación:
Japón